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Background: The vascular endothelial cells are important targets of radiotherapy, which may be involved in
the pathogenesis of radiation pneumonitis (RP). This study investigated the variations of circulating endothelial
progenitor cells (EPCs) and transforming growth factor-beta-1 (TGF-β1) during three-dimensional conformal
radiation therapy (3D-CRT) in patients with non–small-cell lung cancer (NSCLC) and analyzed the correlation
between these variations with the occurrence of RP.
Patients and methods: From November 2008 to November 2009, eighty-four consecutive patients receiving
3D-CRT for stage III disease were evaluated prospectively. Circulating EPCs and TGF-β1 levels were measured
at baseline, every 2 weeks during, and at the end of treatment. RP was evaluated prospectively at 6 weeks after
3D-CRT.
Results: Thirty-eight patients (47.5%) experienced score 1 or more of RP. The baseline levels of EPCs and TGF-β1
were analyzed, no difference was found between patients with and without RP during and after 3D-CRT. By serial
measurement of TGF-β1 and EPCs levels, we found that the mean levels of EPCs in the whole population remained
stable during radiotherapy, but the mean levels of TGF-β1 increased slowly during radiotherapy. TGF-β1 and EPCs
levels were all significantly higher at week 2, week 4 and week 6 in patients with RP than that in patients without
RP, respectively. During the period of radiation treatment, TGF-β1 levels began to increase in the first 2 weeks and
became significantly higher at week 6 (P < 0.01). EPCs levels also began to increase in the first 2 weeks and reached
a peak at week 4. Using an ANOVA model for repeated-measures, we found significant associations between the
levels of TGF-β1 and EPCs during the course of 3D-CRT and the risk of developing RP (P < 0.01). Most of the
dosimetric factors showed a significant association with RP.
Conclusion: Early variations of TGF-β1 and EPCs levels during 3D-CRT are significantly associated with the risk of RP.
Variations of circulating TGF-β1 and EPCs levels during 3D-CRT may serve as independent predictive factors for RP.
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Non–small-cell lung cancer (NSCLC) is the most common
cancer in developed countries. For patients with locally
advanced or medically inoperable disease, radiotherapy
has been an important intervention method. Radiation
pneumonitis (RP) is the acute expression of radio-induced
ung damage. Among the patients received thoracic
radiotherapy, 8% to 13% developed severe toxicity, and
approximately 1.6% died from RP [1]. However, the
underlying molecular and cellular mechanisms of RP
are very complex. Several biological factors need to be
considered for understanding the molecular events in
developing radiation-induced complications in normal
tissues [2-5].
Radiotherapy is an important nonsurgical treatment
for cancer. Recent studies have shown that tumor vascu-
lature and, in particular, the vascular endothelial cells
are important targets of radiotherapy [6,7], which may
be involved in the pathogenesis of RP [8]. The damage
of vascular endothelial cells may increase the infiltration
of inflammatory cells into the pulmonary interstitium
and alveolar. Some believe that damage to vascular
endothelial cells plays a critical role in increasing the
levels of endothelial progenitor cells (EPCs) [9]. EPCs
as well as mature endothelial cells are detectable in the
peripheral circulation [10]. EPCs may appear in the cir-
culation by detaching from activated or damaged vessels.
An increase of circulating EPCs was described in several
pathologic conditions that involve vascular injury or
instability as myocardial infarction and cancer [11,12].
Emerging evidence suggests that circulating EPCs may
provide an endogenous repair mechanism to counteract
ongoing risk factor-induced endothelial injury and there-
fore protect against the development of RP [13]. There-
fore, we postulated that the changes in EPCs levels may
predict the incidence of RP.
Transforming growth factor-beta-1 (TGF-β1) is a pleio-
tropic cytokine that has been found to be highly associated
with the damage of lung architecture. TGF-β1 can regu-
late tissue morphogenesis and inhibit the proliferation of
many cell types [14], which may play an important role in
the pathogenesis of RP [15]. Several recent studies have
proved that radiation induces the expression of TGF-β1
on vascular endothelial cells [16]. TGF-β1 has multiple
effects on vascular endothelial cells. In vivo, TGF-β1 is
one of the key stimuli of endothelial proliferation and
migration and thus plays an essential role in physiological
and pathological angiogenesis [17,18]. Notably, TGF-β1
stimulates directly the proliferation of fibroblasts and
endothelial cell [19]. Previous study proved that TGF-β1
induces angiogenesis in vivo through an indirect mechan-
ism, by up-regulating the expression of VEGF in epithelial
or other cell types [20]. Thus, TGF-β1 activity appears to
be necessary to the loss of lung architecture.We hypothesized that radiotherapy might increase the
mobilization of EPCs by congregating on the damaged
vessels. This study was therefore designed to determine
the changes in circulating EPCs and TGF-β1 during three-
dimensional conformal radiation therapy (3D-CRT) in
patients with NSCLC and to analyze the correlation
between these variations with the occurrence of RP.
Methods
Patient eligibility
This study was approved by the local ethics committee,
and informed consent was obtained from all study
participants. From November 2008 to November 2009,
eighty-four consecutive patients were enrolled in this
prospective study. Criteria for enrollment include: (1)
ages > 18 years; (2) locally unresectable stage III NSCLC
proven either by biopsy or cytology; (3) life expectancy ≥
6 months; (4) Karnofsky performance status (KPS) ≥ 80;
(5) good pulmonary function tests (ratio of forced ex-
piratory volume at 1 second on vital capacity ≥ 50%, ratio
of diffusion capacity for carbon monoxide on alveolar
volume ≥50%). At the time of study entry the patients
had to be free of additional malignant, inflammatory or
ischemic diseases, wounds or ulcers, pulmonary fibrosis
that may influence the results of this study.
Treatment description
As previously reported [21], patients received conven-
tional fractionated RT (2 Gy per fraction, 5 days per week).
The total irradiation dose ranged from 60 to 72 Gy, with a
median of 66 Gy. Target volumes were defined according
to the International Commission on Radiation Units and
Measurements (ICRU) -50 report [22]. The structures of
interest, such as GTV, clinical target volumes, and normal
structures were contoured on multiple computed tomog-
raphy pictures. Doses were calculated taking into account
the tissue density heterogeneity, and dose volume his-
tograms (DVHs) of the lungs were calculated based on
computed tomography–defined lung volumes. Total mean
lung dose (MLD), the percentage of irradiated lung
volume exceeding 20 Gy (V20) and 30 Gy (V30) were cal-
culated from lung DVHs. The total MLD was calculated
as follows: MLD = [(right lung volume ×mean lung dose
to right lung) + (left lung volume ×mean lung dose to left
lung)]/ (left lung volume + right lung volume). The lung
dosimetric factors were calculated with subtraction of the
GTV. Both lungs were considered either as a single paired
organ or as two separate organs. 3D-CRT treatment plan-
ning was performed using the beam’s-eye-view technique.
Megavoltage equipment was used with photon energies of
6 or 15 MV using a multileaf collimator to shape the
irradiation portals according to the target volume. The
first part of radiation used six portal entrances (anterior/
posterior, posterior/anterior and 4 oblique beam) for a
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20 Gy was prescribed using six portal entrances (0°, 51°,
102°, 145°, 215°, and 306°). Six portals were treated each
day. All patients were treated with similar medications
during the observation period.
Evaluation of RP
At 6 to 8 weeks after the end of 3D-CRT, the severity of
RP was determined using the Lent-Soma scale defined
by the Radiation Therapy Oncology Group (RTOG) and
the European Organization for the Research and Treat-
ment of Cancer (EORTC) [23]. Thus, RP was scored
here from clinical symptoms, radiological abnormalities,
and loss of pulmonary function, which include three
subjective scales and two objective scales. Subjective
scales: cough; dyspnea; thoracic pain. Objective scales:
chest x-ray and thoracic CT read by an independent
committee of experts (pneumologists, radiologists and
radiation oncologists); PF tests (reduction of vital cap-
acity and/or diffusion capacity for carbon monoxide on
alveolar volume). All single-scale measures ranged from
0 to 4 in score. The final scoring was equal to the aver-
age of the five scores. RP was defined as the grade ≥1.
Measurement of circulating TGF-β1
Blood samples were collected from patients prior to
treatment (baseline), then every 2 weeks during, and at 4
weeks after the end of treatment (i.e., 5 blood samples).
Blood was collected in tubes containing 7.5% K3 EDTA
and immediately placed on ice. The samples were
centrifuged at 4°C for 30 min at 1000 g within 1 h upon
collection, and then frozen at −80°C for further analysis.
The plasma for TGF-β1 determination was withdrawn
from the middle of the plasma column trying to avoid
the platelet interface. TGF-β1 concentration in plasma
was measured using a specific enzyme immunoassay kit
from immunotech (Biosource, USA).
Isolation and quantification of EPCs by flow cytometry
Blood samples were collected from patients prior to
treatment (baseline), then every 2 weeks during, and at
4 weeks after the end of treatment. Monocytes were
isolated and purified from 20 ml of peripheral blood. In
brief, 20 ml blood diluted 1:1 in phosphate-buffered
saline (PBS) was layered on top of lymphoprep density
gradient media at 1.077 plus or minus 0.001 g/ml
(Pharmacia Biotech, Uppsala, Sweden) to separate per-
ipheral blood mononuclear cells (PBMCs). Tubes were
centrifuged for 30 minutes at 400 g. PBMCs on top of
the separation media were carefully collected and then
washed 3 times with PBS.
CD34+ monocytes were isolated from PBMCs using
immunomagnetic CD34 microbeads (Miltenyi direct
CD34 progenitor cell isolation kit, Miltenyi Biotech,Bergisch-Gladbach, Germany) as reported previously [24].
After the magnetic labeling of the cells, the suspension
was loaded onto a MACS Column (MS Columns, Miltenyi
Biotec) which was placed in the magnetic field of a MACS
Separator (Octo MACS Cell Separator, Miltenyi Biotec).
The magnetically labeled CD34+ cells were retained
within the column. After removing the column from
the magnetic field, the magnetically- retained CD34+
cells were eluted as a positively-selected cell fraction.
The CD34+ cells were counted with the Neubauer
counting chamber. After the positive selection, CD34+
MNCs were counted by FACS (fluorecenceactivated
cell sorting) analysis. The number of CD34+ cells were
quantified and expressed as number of cells per milliliter
of blood. All samples were measured in duplicate and
the values averaged. For all assays the intra-observer
and inter-observer variation coefficient was less than
5%, respectively.
Statistical analysis
Continuous data were expressed as mean ± SD, and
discrete data were given as counts and percentages. A
student’s t-test was used to evaluate the relationship
between the clinical, functional, and dosimetric factors
on RP. Pearson Chi-Square test was used to compare
categorical variables, and independent-samples T test
or one-way ANOVA were used for quantitative variables,
as appropriate. Linear regression analysis was employed to
determine the correlation between the changes of EPCs
and TGF-β1 in the same patient. In the univariate analysis,
the occurrence of RP and potential prognostic features
were analyzed with the standard statistical analysis
methods. An SPSS software package (version 13.0; SPSS
Inc) was adopted for analysis and a value of P < 0.05
was regarded as statistically significant.
Results
Patient characteristics
Of the 84 patients enrolled, four patients were excluded
from analysis due to incomplete treatment (1 patient),
unsatisfactory blood sampling (1 patient) and cancer
progression (2 patients). Finally, 80 patients were enrolled
in this study including 48 males and 32 females. Their
ages ranged from 38 to 70 years, with a mean age of
58.5 years. There were 43 squamous cell carcinomas, 31
adenocarcinomas, 3 large cell carcinomas and 3 others.
Seven patients had chronic obstructive pulmonary disease,
3 with cardiovascular disease, and 3 with diabetes. No
patients had any evidence of interstitial pulmonary
fibrosis. Chemotherapy was done before radiation in 21
patients (26.3%), and concurrent and post chemother-
apy was done in 35 patients (43.8%). The used regimens
for concurrent chemotherapy were combinations of
etoposide and cisplatin (22 patients) or docetaxel and
Table 1 Baseline clinical characteristics of the
study group
Characteristics Number of patients Percentage (%)















Squamous cell 43 53.8
Large cell carcinoma 3 3.7
Other 3 3.7
Tumor site (lobe)





















Abbreviations: COPD: chronic obstructive pulmonary disease, KPS: Karnofsky
performance status.
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included weekly taxol (4 patients) or cisplatin (1 patient).
The patient characteristics are summarized in Table 1.
The incidence of RP
RP at 6 to 8 weeks after the end of 3D-CRT are shown
in Table 2. At 6 to 8 weeks, RP score 1 or more occurred
in 38 (47.5%) of the 80 patients evaluated, including
Grade 1 in 28 patients (35%), Grade 2 in 7 patients
(8.75%), Grade 3 in 2 patients (2.5%). One patient (1.2%)
suffered RP of Grade 4 and died of aggravation.
Changes of TGF-β1
The TGF-β1 levels at baseline, during, and after 3D-CRT
were shown in Figure 1a. At baseline, the median TGF-
β1 concentrations for RP patients and non-RP patients
were 4.38 ng/ml (range, 3.24-6.23 ng/ml) and 4.30 ng/ml
(range, 3.11-6.35 ng/ml), respectively. There was no sig-
nificant difference between patients with and without RP
(Table 3). During the period of 3D-CRT, the TGF-β1
levels in the RP group tended to increase significantly
and reached a peak at 6 weeks. While in the non-RP
group, the levels of TGF-β1 tended to increase relative
to their pretreatment level, but no significant difference
was found (Figure 2). We also performed an ANOVA
model for repeated-measures for analysis of chrono-
logical changes in TGF-β1 levels and found that there
were significant correlations between the TGF-β1 levels
during the time course of 3D-CRT and the risk of devel-
oping RP.
Changes of EPCs
We determined the number of EPCs (CD34+ cells) in
the peripheral blood with flow cytometry. At baseline,
the number of EPCs in RP patients was similar to that in
the non-RP patients (1201.4 ± 311.7 cells/ml vs 1164.6 ±
349.9 cells/ml) (Table 3). The number of circulating
EPCs at baseline, during, and after 3D-CRT did not vary
significantly (Figure 1b). The analysis of variance showed
that the occurrence of RP was significantly correlated
with the variation of EPCs levels during 3D-CRT. As
shown in Figure 3, the EPCs numbers in both RP pa-
tients and non-RP patients reached a peak at 4 weeks,
and the difference of EPCs levels between patients who
developed RP and those who did not was statistically
significant during and after 3D-CRT.
Association between the biomarkers and the clinical
diagnosis of RP
We made statistical calculations and found that there
was positive correlation between EPCs and the diagnosis
of RP (r = 0.25, P < 0.01) and TGF-β1 and the diagnosis
of RP (r = 0.55, P < 0.01). We also analyzed the correl-
ation between the changes of EPCs and TGF-β1 in the
Table 2 Scoring of the 80 patients evaluated for RP
after treatment






#Radiation pneumonitis was defined as the development of pulmonary toxicity
of score ≥ 1.
Table 3 Comparison of TGF-β1 and EPCs at baseline in
patients with and without RP
Levels at
baseline
RP No RP P*
Mean SD Mean SD
TGF-β1, ng/ml 4.54 ± 0.78 4.60 ± 0.89 0.73
EPCs, cells/ml 1201.4 ± 311.70 1164.6 ± 349.90 0.62
Abbreviations: RP: radiation pneumonitis, SD: standard deviation, TGF-β1:
transforming growth factor-beta-1, EPCs: endothelial progenitor cells.
* Independent-samples T test.
Liu et al. Radiation Oncology 2013, 8:189 Page 5 of 9
http://www.ro-journal.com/content/8/1/189same patient and found that there was a positive correl-
ation between them (r = 0.12, P < 0.05).
Clinical, functional, and dosimetric factors are predictive
for RP at 6 to 8 weeks
The results concerning the predictive impact of clinical,
functional and dosimetric factors have been shown in
Table 4. In the univariate analysis, except for weight
loss ≥ 5% (P = 0.05), no other clinical or functional factors
at the baseline were significantly associated with the
occurrence of RP. However, many dosimetric factors
showed an association with RP. For the lung as a paired
organ, V20 and V30 at the time of inclusion were statisti-
cally significant factors for the occurrence of RP (P = 0.02,
and P = 0.001, respectively). MLD was also significantly
associated with RP (P = 0.008).
Discussion
RP is a serious and potentially lethal treatment-related
complication for lung cancer. The first finding of this
study is that there was a high incidence (47.5%) of RP in
NSCLC treated with 3D-CRT, which is higher than that
in previous report [25]. The lack of consensus on uniform
criteria for defining RP makes it difficult to diagnose,
explain and compare the incidence and severity of RP.
In approximately 28% of RP patients, the diagnosis isFigure 1 Changes of TGF-β1 and EPCs during and after the treatment
of transforming growth factor-beta-1 (TGF-β1) at baseline, during, and after
b. Change of EPCs during and after the treatment. Variations of circulating
treatment in the whole group. Values are presented as mean ± S.E.uncertain due to confounding factors [26]. In this article,
we used a classification derived from the Lent-Soma
scale defined by the RTOG and the EORTC [23]. This
classification is based not only on clinical evaluation but
also on measurements of loss of pulmonary function and
radiological changes. In our study, the majority (35.0%)
of RP patients suffered Grade 1, whereas 8.75% suffered
Grade 2, 2.5% suffered Grade 3, and 1.2% suffered
Grade 4. The high rate of RP observed in our study is
thus mainly due to score 1 toxicity, which is similar to
the results reported by other prospective studies using
various scoring scales [27-29].
As all of us have known, the occurrence of pneumon-
itis is unpredictable. Therefore, reliable biochemical or
cellular markers in identifying individuals at a high risk
of developing RP are most desirable for early treatment
modifications in order to avoid serious complications.
These biomarkers may also allow the selection of
patients who may be able to tolerate higher doses of
radiation. Microvascular injury is a prominent feature
of normal tissue radiation injury and plays a critical
role in both acute (inflammatory) and chronic (fibrotic)
radiation responses. Injury of the vascular endothelium
is presumed to play a central role in the response of
most normal tissues to ionizing radiation and to the
progressive nature of chronic radiation fibrosis. This is
particularly true for chronic radiation toxicity, in which
microvascular injury seems to be a key to the unique. a. Change of TGF-β1 during and after the treatment. Variations
treatment in the whole group. Values are presented as mean ± S.E.
endothelial progenitor cells (EPCs) at baseline, during, and after
Figure 2 Change of TGF-β1 during and after the treatment. Variations of transforming growth factor-beta-1 (TGF-β1) at baseline, during, and
after treatment in the RP group and the non-RP group. Values are presented as mean ± S.E. ‡P < 0.01 versus the baseline; †P < 0.05 versus the
baseline; #P < 0.01 versus the control group; *P < 0.05 versus the control group.
Figure 3 Change of EPCs during and after the treatment. Variations of endothelial progenitor cells (EPCs) at baseline, during, and after
treatment in the RP group and the non-RP group. Values are presented as mean ± S.E. ‡P < 0.01 versus the baseline; †P < 0.05 versus the baseline;
#P < 0.01 versus the control group; *P < 0.05 versus the control group.
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Table 4 Clinical, functional, and dosimetric factors on RP
Characteristics RP No-RP P
Age Mean (range) 58.5 (38–70) 59 (40–70) 0.83
Gender (Male/Female) 25/13 23/19 0.36
KPS Mean (range) 90.5 (80–100) 91.9 (80–100) 0.40
AJCC clinical stage (IIIA/ IIIB) 18/20 17/25 0.53
Histology (AD/SQ/LA/OT) 17/20/1/0 14/23/2/3 0.30
Tumor site (UM/LO) 29/9 28/14 0.34
Comorbidity (COPD/CA/DI) 2/1/0 5/2/1 0.80
Smoking history (NO/CU) 20/18 14/28 0.81
Chemotherapy (Yes/ No) 30/8 26/16 0.10
V20 Mean (range) 38.2 (8.6-63.3) 29.6 (8.9-60.2) 0.02
V30 Mean (range) 33.9 (7.9-48.5) 25.6 (6.6-51.0) 0.001
DLCO (%) Mean (range) 87.4 (61.3-99.4) 85.7 (65.4-98.7) 0.53
FEV1 (%) Mean (range) 86.3 (63.6-99.0) 83.4 (66.6-99.4) 0.24
FVC (%) Mean (range) 90.9 (75.6-99.6) 89.5 (74.3-99.4) 0.38
MLD Mean (range) 16.7 (5.9-25.6) 14.0 (7.9-21.3) 0.008
Weight loss≥ 5% (Yes/ No) 18/20 11/31 0.0
Abbreviations: KPS: Karnofsky performance status, AD: Adenocarcinoma, SQ:
Squamous cell, LA: Large cell carcinoma, OT: Other, UM: Upper&middle, LO:
Lower, COPD: chronic obstructive pulmonary disease, CA: Cardiovascular
disease, DI: diabetes, NO: Nonsmoker, CU: Current or ex smoker, V20:
Percentage of irradiated lung volume exceeding 20 Gy, V30: Percentage of
irradiated lung volume exceeding 30 Gy, DLCO: Diffusion capacity for carbon
monoxide, FEV1: Forced expiratory volume at 1 second, FVC: Forced vital
capacity, MLD: mean lung dose.
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represent a subset of bone marrow derived cells that
undergo mobilization secondary to a stimulus, circulate
in the peripheral bloodstream where they home to sites
of neovascularization, and differentiate into endothelial
cells on site. Circulating EPCs may provide an endogenous
repair mechanism to counteract ongoing risk factor-
induced endothelial injury and therefore protect against
the development of RP [31].
In our study, we first reported the correlation between
the variations of circulating EPCs levels before, during
and after 3D-CRT and the risk of RP in patients with
NSCLC. We found that there was a statistically significant
correlation between the variation of EPCs during and
after 3D-CRT and the risk of developing RP, but no
statistically significant correlation was found between
the baseline level of EPCs and the risk of developing
RP. EPCs levels began to increase in the first 2 weeks
and reached a peak at week 4. EPCs levels were all
significantly higher at week 2, week 4 and week 6 in
patients with RP than that in patients without RP,
respectively.
In acute situation, radiation causes endothelial cell
apoptosis, increases vascular permeability, expression of
chemokines and adhesion molecule. Others have recently
demonstrated that vascular repair and reendothelializationafter injury is enhanced by circulating EPCs [32,33].
Given these data, we speculate that 3D-CRT increases
the mobilization of circulating EPCs, which may con-
tribute to the repair of vascular and the enhancement
of neoangiogenesis. Therefore, circulating EPCs levels
are quantified to assess endothelial repair capacity and
may be related to the rate of RP. Previous study has
proved that irradiation can cause severe endothelium
injury, which can start the mobilization of EPCs. On
the other hand, endothelium injury also can induce
extrinsic EPCs homing to the tissues [34]. Therefore,
we presumed that the elevation of the number of circu-
lating EPCs might represent a mechanism to enhance
vascular health and reduce the damage of RP.
In this article, we have evaluated the utility of TGF-β1
as a predictor of RP. We found that the baseline levels
of TGF-β1 in RP patients (4.38 ng/ml, range 3.24-6.23
ng/ml) were similar to that in non-RP patients (4.30 ng/
ml, range 3.11-6.35 ng/ml). This finding is contrary to
the result reported by Rübe [35]. The TGF-β1 levels
during the period of 3D-CRT were significantly higher
in patients with RP than that in patients without RP. We
also found that the changes of TGF-β1 level during the
course of 3D-CRT appeared to be useful in identifying
patients at risk for developing RP. This finding is similar
to the results by other researchers [36,37]. TGF-β1 plays
a key role in tissue response to radiotherapy as a master
switch for development and persistence of fibrosis [35].
In the lung parenchyma, TGF-β1 is synthesized by a
large variety of cells, including platelets, leukocytes, and
erythrocytes and its release into the plasma might be
caused not only by the method of blood collection but
also by pathological conditions of these cells. Therefore,
there is conflicting data regarding the predictive ability
of TGF-β1. Some clinical trials demonstrated that the
incidence of RP was significantly correlated with plasma
TGF-β1 level. The incidence of RP was significantly
higher when TGF-β1 levels increased during radiothe-
rapy or it failed to normalize after radiotherapy. Others
also reported that there was a positive correlation be-
tween the levels of TGF-β1 before and during RT and
the risk for developing RP [38].
Although TGF-β1 levels remained stable in the whole
population during 3D-CRT, its circulating levels showed
a statistically significant opposite evolution between pa-
tients with RP and patients without RP. TGF-β1 levels
remained significantly elevated throughout the treatment
in RP patients in comparison with that in non-RP patients,
with a significant peak elevation at 6 weeks of treatment.
TGF-β1 is a multifunctional cytokine involved in the
regulation of immunologic and inflammatory response.
The mechanisms through which TGF-β1 performs are
complex, which involve both the inhibition of epithelial
cell proliferation and the development of tissue fibrosis
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of TGF-β1 from a latent complex that can occur at
radiation doses as low as 0.5 Gy [39]. TGF-β1 has mul-
tiple effects on vascular endothelial cells. It can induce
angiogenesis [40]. Because TGF-β1 and EPCs mutually
regulate vascular endothelial cells and can be considered
in the complex interactive network, their levels during
3D-CRT may reflect the damage of vascular by radiation.
In our study, the evolution of circulating TGF-β1 and
EPCs levels during 3D-CRT was significantly associated
with the risk of RP and seemed to be independent
predictive factors for RP. This means that such varia-
tions could be an additional predictive tool to be used
in association with dosimetric parameters and clinical
character such as MLD, V20, V30 or weight loss ≥ 5%
for a more precise evaluation of the risk of RP.
Conclusion
In this study, we demonstrated that the variations of
TGF-β1 and EPCs levels during 3D-CRT are significantly
associated with the risk of RP. In the patients who deve-
loped RP, both TGF-β1 and EPCs level increased and
reached a peak at 6 weeks and 4 weeks during 3D-CRT,
respectively. On the contrary, the levels of TGF-β1 and
EPCs in the patients who didn’t develop RP remain rela-
tive stable. Further research should be done to further
identify biomarkers that might one day allow us to give
rise to novel and specific prevention strategies for RP.
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